Podcasts about nvl

In today's episode, we had the pleasure of speaking with Stephen Liu, MD, about the potential role for zidesamtinib (NVL-520) for the treatment of patients with advanced non–small cell lung cancer (NSCLC) harboring ROS1 rearrangements. Dr Liu is an associate professor of medicine at Georgetown University, as well as the director of Thoracic Oncology and head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC. In our exclusive interview, Dr Liu discussed the current standards and challenges for treating patients with ROS1-positive disease, the unique mechanism of action of zidesamtinib, and how positive findings from the phase 1/2 ARROS-1 trial (NCT05118789) may help position this agent in the ROS1-positive NSCLC treatment paradigm.

With the weather getting colder, debates the controversy that swirls around the age old decision--sweatshirt or hoodie (hoodie, ofc). Looks like students are leaning toward keeping the Internet over basic heat and A/C. Tomlin updates the penny shortage while hosting a "Penny War" in Student Government for spirit week. AI could replace teachers. Volleyball drops a tough one in NVL semis, and the NVL CHAMPS, Girls Soccer, swings by: Coach Jillian Jackman and Captains Avery DiGiovanna and Giulianna Celotto.

With all the traffic on Pine Bridge this morning, the crew got off to a late start and even their guest was later than expected. Add to that the camera still wasn't working and you get a hot mess of Tuesday. But the show must go on! Theoretically speaking, of course. And it did.Leah Zainc, NVL Champion Cross Country runner, was the guest of the hour.Girls Soccer won NVL tournament and the Dodgers finally finished an 18-inning marathon, about two minutes ago.

Amato smells. Well, he smelled a skunk on the drive in to work, then began reminiscing about missing skunks (I don't know, I just write the cutlines for the episode). Tomlin finds a bunch of stories about ancient artifacts and dead bodies and Decker notes that post season play is here. The girls cross country team landed 3rd overall in the NVL with Leah Zainc finishing in 1st place, and the boys came in at 7th. Boys soccer missed post season by one match with their loss to Oxford.

Decker realizes that Columbus Day is still a week away, experts reassess how quickly AI will take over the world and Woodland sports is showing strength in the NVL.Sports team mascot count: 15:10 (wins/losses)

In today's episode, we had the pleasure of speaking with Alexander Drilon, MD, about the phase 1/2 ARROS-1 trial (NCT05118789) investigating zidesamtinib (NVL-520) in TKI-pretreated patients with advanced ROS1-positive non–small cell lung cancer (NSCLC). Dr Drilon is chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center in New York, New York. In our exclusive interview, Dr Drilon discussed the efficacy data and implications of the ARROS-1 trial, highlighted the unique mechanism of action of zidesamtinib, noted the high central nervous system (CNS) response rates and favorable safety profile associated with the agent, and emphasized the potential for zidesamtinib to become a standard first-line therapy in the NSCLC treatment paradigm, especially for patients with prior TKI resistance or CNS disease.

Deutschlands größter Rüstungskonzern Rheinmetall will die Militärsparte Naval Vessels Lürssen (NVL) der Bremer Lürssen Werft kaufen. Die Kartellbehörde muss das noch absegnen - wir wagen einen Blick auf die Strategie von Rheinmetall, gucken insgesamt auf die boomende Rüstungsindustrie und auf die Auswirkungen für Mitarbeitende. Unsere Folge zur neuen Rheinmetall-Fabrik in Unterlüß: https://www.ardaudiothek.de/episode/urn:ard:episode:04826543e4dbbbf4/ Podcast "Streitkräfte und Strategien": https://www.ardaudiothek.de/sendung/streitkraefte-und-strategien/urn:ard:show:794d51bd58e1747c/

Dave Palm is an American beach volleyball coach, professional player, and indoor coach. His accomplishments on the AVP and NVL scene are as well-documented as they are commendable. And it seems that the work he is doing as coach only showed he was just getting started. He resides in Florida and is the founder of "Palm Coast Volleyball Club." 01:31 - The transition from player to coach, and how seamless it was by appearance 12:11 - paid to coach, caring is free, tips for indoor tryouts, on the surface, and behind the scenes, regional strategies on how they hold onto a power dynamic 19:21 - finding out where you are one the indoor depth chart and what it means to your playing time, playing on a "2" team for more in-game reps 27:19 - concerns that parent air coming in, most likely generating from their experience from previous clubs or having it be their kids' first club 34:10 - skills and advantages that indoor players playing beach for the summer during he indoor off-season 40:16 - what percentage of the game is mental, and how much do you implement it in practice? Plus, the recruiting process of coaches 53:05 - what coach inspired you to a point where you will never forget them? About "Manny," plus, books to inspire the athlete #nyvarsitysports #optionpodcast

In this JCO Article Insights episode, host Peter Li summarizes "Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST" by Pérol et al, published April 03, 2025, followed by an interview with first author, Dr Maurice Pérol. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Peter Li: Welcome to this episode of JCO Article Insights. I am Dr. Peter Li, JCO's editorial fellow, and today I am joined by Dr. Maurice Pérol on “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” by Pérol et al. At the time of this recording, our guest has disclosures that will be linked in the transcript. Before we start our interview, I want to give our listeners a quick summary of the TRUST study. For those tuning in, the TRUST study is a phase II, single-arm, open-label, nonrandomized, multicenter trial looking at the efficacy and safety of a novel, next-generation ROS1 TKI, taletrectinib, in advanced ROS1-mutated non–small cell lung cancer. While a relatively rare mutation, the prevalence of ROS1 mutations ranges from 0.9% to 2.6% of patients, with a third of patients presenting with brain mets at diagnosis.Current FDA-approved therapies include crizotinib, entrectinib, and repotrectinib, which have varying degrees of efficacy, in-coming with trade-offs in CNS penetrance and safety with newer generations, particularly in the realm of neurological side effects, highlighting an unmet need in this arena. A total of 273 patients with advanced non–small cell lung cancer with confirmed ROS1 mutation were recruited for this study. 160 patients were TKI-naive, while 113 were TKI-experienced with either crizotinib or entrectinib. Patients with asymptomatic brain mets were also allowed to enroll. In the TKI-naive arm, the median age was 57, with 91% of patients having stage IV disease, 20% having no more than one cycle of chemo, and 23% having brain mets at baseline. In the TKI-experienced arm, the median age was 53, with 97% having stage IV disease, 37% having received prior chemo, and about 50% having brain mets. Furthermore, about 10% of the study population had received entrectinib, while more than 90% had received crizotinib. About 10% had a known G2032R acquired resistance mutation. Taletrectinib was dosed at 600 mg daily until disease progression or unacceptable toxicities. The primary endpoint was overall response rate, with secondary endpoints being disease control rate, duration of response, time to response, and progression-free survival. For those with brain mets, intracranial overall response rate and disease control rate were also assessed. Median follow-up time was about 21 months in both cohorts. In the TKI-naive cohort, the overall response rate was 89%, with 8 patients achieving a complete response. Disease control rate was 95%, with a median duration of response of 44.2 months. Time to treatment response was about 1.5 months. Median progression-free survival was 45.6 months, with 52.6% not having progressed at 3 years. While overall survival data were immature, 66% of patients were still alive at 3 years. In the pretreated cohort, overall response rate was 56%, with 5 patients achieving a complete response. Overall response rate was 53% for those who were crizotinib-pretreated and 80% for the entrectinib-pretreated patients. Disease control rate was 88%, and median duration of response was about 16.5 months. Time to treatment response was also 1.5 months, and median progression-free survival was 9.7 months. Median overall survival was not reached, but 77.5% of patients were still alive at 1 year. Responses were consistently seen across subgroup analyses. 17 TKI-naive and 32 TKI-pretreated patients had measurable brain mets. In the TKI-naive arm, intracranial overall response rate was 77%. Disease control rate was 88%, and duration of response was 15 months. In the TKI-pretreated arm, intracranial overall response was 66%, with one patient achieving complete response. The disease control rate was 94%, and duration of response was about a year. For the 13 patients who had a known G2032R mutation, a 62% response rate was noted. Most common treatment-related side effects were AST/ALT elevation, nausea, and vomiting, with most being grade 1 or 2. Most common neurological side effects were dizziness, dysgeusia, and headache. Again, most were grade 1. QTc prolongation is another important adverse event to note, occurring in about 18% of all patients. Discontinuation rate from treatment was only 7%. There were three treatment-related deaths in this study: one from hepatic failure, one from pneumonia in the naive arm, and one from liver dysfunction in the pretreated arm. Dr. Peter Li: Maurice, thank you so much for joining us today to talk about your paper. Would you mind just giving yourself a brief introduction to the listeners out there of who you are? Dr. Maurice Pérol: So, my name is Maurice Perol. I'm a thoracic oncologist working in the Cancer Center of Lyon in France. And I'm involved in clinical research in thoracic oncology. I've been involved for many years now. Dr. Peter Li: Okay. And for listeners out there, don't forget, he's also the primary author of the paper that we just talked about. So, Maurice, let's begin. Can you tell our listeners what is the significance of your study? Dr. Maurice Pérol: Well, the results of these two large phase II studies - TRUST-I, which has been conducted in China, and TRUST-II, which was a global, worldwide phase II study - so, the results place taletrectinib as the TKI with the most favorable efficacy-tolerability ratio of the available ROS1-targeting TKIs, especially in frontline therapy. And this is based on the response rate, which was very impressive, the CNS penetration with a great CNS activity, the duration of response with a compelling 45 months median PFS in frontline setting. The level of activity in pretreated patients after crizotinib or entrectinib was also impressive and similar to that of repotrectinib, for example, but with a more favorable neurological tolerance profile. The toxicity is mainly represented with grade 1 or 2 transaminase elevation, but without clinical symptoms, and GI toxicity, but mainly grade 1 and 2. The neurological toxicity is low, especially for dizziness, showing that taletrectinib spares TrKB in a large part. And finally, there is also a decrease in toxicity over time, especially for GI toxicity and liver toxicities, which allows a very long and a prolonged administration, which is very important in this setting. Dr. Peter Li: These are all excellent points. Can you tell the listeners if there are any limitations that we should be concerned about, about this study? Dr. Maurice Pérol: Sure. This data comes from single-arm phase II studies. So, this is not comparative data. And a phase III trial, which compares taletrectinib to crizotinib, is ongoing to evaluate the superiority of taletrectinib over the standard of care. Another limitation comes from the lack of systematic brain imaging at each tumor evaluation in patients without brain metastases at baseline, not allowing to assess the intracranial PFS in all patients, and which did not allow us to assess the CNS protective issue from taletrectinib, especially in patients without brain metastases at baseline. Dr. Peter Li: Another question that I have is, with this novel TKI now available, how would you recommend the sequencing of these drugs? Would you start with someone on an alternate TKI and then reserve taletrectinib second line or later? Or would you use it upfront? Or does it depend? Dr. Maurice Pérol: Well, it is a very important question, as we have now different available TKIs. Looking at the efficacy-toxicity balance, I would strongly favor the use of taletrectinib in frontline setting, in first line. The response rate, the CNS activity, the duration of response with a very compelling 45 months median PFS, and moreover, the good tolerance profile over time are strong arguments in favor of giving taletrectinib in frontline. Generally speaking, the use of the most active agent as frontline treatment in lung cancer depending on an oncogenic addiction is probably the best way to improve the patient's outcome. This is true for patients with EGFR mutation, for patients with ALK fusions, and this is probably also true for patients with ROS1 fusion. So, I would probably argue in favor of a frontline use of taletrectinib. Dr. Peter Li: Listeners are going to ask, well, if you use taletrectinib upfront, then what are you going to use second line once they progress? Dr. Maurice Pérol: Well, we have some new compounds which are under development today. For example, the NVL-520, which is a very interesting compound, which seems also to be active in case of resistance mutation. But I do think that we have to use the best-in-class TKI in frontline because, you know, the extension of PFS after acquired resistance you can obtain with a second-line TKI is always shorter than the benefit you can obtain by using the most active agent in frontline. And this is true for the majority of oncogenic addiction in lung cancer. Dr. Peter Li: That makes sense. I also noticed that cognitive impairment wasn't listed in the safety table. Is that not an issue that you've observed at all with taletrectinib, or is it still an issue but less so because, like you mentioned earlier, because of its higher selectivity? Dr. Maurice Pérol: Well, this is a good question because we have some ROS1-targeting TKIs like repotrectinib, entrectinib, and even lorlatinib, with some neurological adverse events and some cognitive issues. Taletrectinib is a very selective ROS1-targeting TKI, and it spares very well the TrKB, for example, explaining that we did not observe any cognitive impairment with taletrectinib in the TRUST study, showing also with the low level of other neurological adverse events, dizziness, dysgeusia, for example, the high selectivity of the compound and the preservation of TrKB. So, this is very important when you consider the long duration of treatment in those patients with ROS1 fusion. If you have to take a drug for more than 2, 3, or 4 years, of course, the neurological adverse events are very important, and they can clearly impair the quality of life. So, this is a very important point, the very low level of neurological toxicity of taletrectinib. Dr. Peter Li: And I think that goes to say why you would favor using it frontline as well compared to entrectinib or repotrectinib. Last question that we have for you is: well, what's next? You mentioned there's a phase III trial comparing it to crizotinib. I think one of the questions that a lot of us would have is: why not compare it to one of the newer agents as a comparator arm? Dr. Maurice Pérol: Well, this is a good question. Crizotinib remains the standard of care in many countries for ROS1-positive advanced non–small cell lung cancer outside of the US, especially in Europe, and in particular in patients who do not have brain metastases at diagnosis. Entrectinib has a better CNS penetration, but it did not achieve a better PFS than crizotinib in phase I/II trials, and clearly, it has a less favorable tolerance profile with weight gain, edema, and neurological adverse events. Repotrectinib has overall a level of activity which seems close to that of taletrectinib. So, it makes it difficult to consider a comparative trial that would, for example, test taletrectinib in comparison with repotrectinib because this kind of study would need a very large number of patients and a very late readout. Considering if you have a median PFS of more than 3 or 4 years, it would be very difficult to have results in before 4-5 years. So, from a pragmatic point of view, the comparison of taletrectinib to crizotinib is probably the best way to evaluate in a phase III setting the level of activity of taletrectinib, especially in the CNS, because this study will probably allow us to assess the CNS protective effect of the compound for patients without brain metastates at baseline. So, I think probably it's a pragmatic study that will allow us to confirm the high level of activity and the good tolerance profile of taletrectinib. Dr. Peter Li: Well, thank you, Maurice, so much for speaking about the JCO article, “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” and for all your valuable input today. Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries, and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Jeff Samuels is an American Professional Beach Volleyball Player, Entrepreneur, and Model. He is also a spokesperson for Hyundai. The prosperity he is enjoying in his sport is well-documented. From the AVP, FIVB, NVL, to regional tournament wins, this versatile player is fun to watch, wherever the venue may be. 01:50 - Jon Jones retires, charged, the evolution of how we choose our role models, "Being like Mike," what it meant before and what it means now 12:14 - People who are not "big's" who play big at the net, finding out what defines you and to what end, working with different partners and what they bring 30:11 - Should Jon Jones not be on the GOAT list, who are your top 5 NBA GOATS, how good is Demetrious Johnson? Plus, loving Muhammad Ali, athletes who were activists, 42:55 - Volleyball is life, and at the same time, it is not. Playing multiple sports and the compare and contrast of that "feeling." Plus, does success change players, who they remember and associated with, and when is this a good thing or a bad thing, what is "conversational memory." 55:33 - When your escapism becomes your career, about the HBO series "The Wire," coming back from the roller coaster ride in 2019, re-shaping himself for the next evolution 1:06:22 - different versions of ourselves, the Motherlode, inside beach volleyball - what are we fighting over? Plus, is there a "hunger games" happening in the volleyball climate? About Chase Frishman 1:20:41 - The league, calculated risks, things changing vs things staying the same, Eric Cam - the one-man team - raised the bar for all, the disc gold promotion, thoughts from the comment section, the creation of city vs city, introducing 4's, 1:58:04 - What does it take to be and stay marketable 2:06:50 - How did he transition to coaching so seamlessly? #nyvarsitysports #optionpodcast #avp #beachvolleyballworld Available on iTunes and Spotify:

Ende März werfen drei Fachgesellschaften bei der NVL KHK hin. Sie üben deutliche Kritik an der Leitlinie. Was steckt hinter der Kritik? Wir schauen uns die Argumente und Quellen hinter den 8 Punkten im EvidenzUpdate-Podcast genauer an.

This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in non-small cell lung cancer (NSCLC), hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain.      In this episode, Dr Isabel Preeshagul and Dr Eric Singhi provide the benefit of their experience when discussing how to approach different treatment scenarios in HER2-mutant NSCLC.   The conversation unfolds to cover: • Ways to distinguish HER2 alterations from other alterations on biomarker reports  • The latest efficacy and safety data of currently approved and emerging treatments for HER2-altered NSCLC   • The potential CNS activity of these treatments in patients with HER2-mutated NSCLC  • How the treatment pathway may look in the near future      Clinical takeaways • In NSCLC, HER2-positivity includes mutations, amplifications and overexpression. It's important to distinguish HER2 alterations from EGFR mutations, particularly exon 20 insertions, when interpreting next-generation sequencing (NGS) results  • Trastuzumab Deruxtecan (T-DXd) is currently the only approved targeted agent for HER2-altered NSCLC in the 2nd-line setting. It shows promising efficacy, especially in HER2-mutant cases, but has limited brain penetration and is associated with notable side effects, including pneumonitis, which requires close monitoring  • Emerging TKIs, such as zongertinib, BAY 2927088 (sevabertinib), and NVL-330, target HER2-mutations and have shown high response rates and CNS activity in early studies, without ILD/pneumonitis. These treatments come with unique side effects like diarrhoea and rash, which can be managed with supportive care  • CNS metastases are common, with up to 30% of HER2-altered NSCLC patients presenting with or quickly developing CNS metastases. Current large molecule therapies (like T-DXd) have limited brain penetration, making small-molecule TKIs, like zongertinib, BAY 2927088 (sevabertinib), and NVL-330, promising for their potential CNS activity • Current standard 1st-line care for HER2-mutant NSCLC remains platinum-based chemotherapy ± immunotherapy. Targeted agents (like T-DXd) are generally reserved for 2nd-line use, but ongoing trials are evaluating the move toward frontline therapy Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for the next episode

Mit einer neuen SCOT-HEART-Publikation liegen jetzt 10-Jahres-Daten vor. Im neuen EvidenzUpdate-Podcast schauen wir, was sie für die CCTA bei V.a. KHK bedeuten. Wir reden über die Zukunft der NVL. Und jetzt neu: Scherers Soundmaschine.

La Dra. Tannia Soria, oncóloga clínica adscrita al Hospital de Solca en Quito, Ecuador, en conjunto con el Dr. Carlos Cabrera, oncólogo médico adscrito al UOMi Cancer Center en Barcelona, España nos presentan un resumen de los estudios que consideran más relevantes en el ámbito del cáncer de pulmón expuestos durante el Congreso de ESMO 2024. ALKOVE-1: estudio fase I/II el cual evalúa NVL-655, un inhibidor de tirosina quinasa de cuarta generación específico para ALK en pacientes con cáncer de pulmón de células no pequeñas avanzado y otros tumores sólidos. ARROS-1: estudio fase I/II del inhibidor altamente selectivo ROS1, se evalúa NVL-520 en pacientes con cáncer de pulmón de células no pequeñas avanzado y otros tumores sólidos. MARIPOSA-2: estudio fase III, abierto y aleatorizado de amivantamab y lazertinib en combinación con quimioterapia basada en platino en comparación con quimioterapia basada en platino en pacientes con cáncer de pulmón de células no pequeñas localmente avanzado o metastásico con mutación de EGFR que han progresado tras tratamiento con osimertinib. MARIPOSA: estudio fase III, el cual tiene como objetivo evaluar la eficacia de la combinación de amivantamab y lazertinib vs. osimertinib, en pacientes con cáncer de pulmón de células no pequeñas localmente avanzado o metastásico con mutación EGFR. RELATIVITY-104: estudio fase III, aleatorizado y doble ciego de quimioterapia neoadyuvante más nivolumab vs. quimioterapia neoadyuvante más placebo, seguida de resección quirúrgica y tratamiento adyuvante con nivolumab o placebo para participantes con cáncer de pulmón de células no pequeñas resecable en estadio II-IIIB. BR.31: estudio fase III, prospectivo, doble ciego, controlado con placebo, en el cual no se demostró mejoras en la supervivencia libre de enfermedad con el uso de durvalumab adyuvante en pacientes con cáncer de pulmón de células no pequeñas que se sometieron a una resección quirúrgica completa y quimioterapia opcional.     Fecha de grabación: 07 de octubre de 2024.                               Todos los comentarios emitidos por los participantes son a título personal y no reflejan la opinión de ScienceLink u otros. Se deberá revisar las indicaciones aprobadas en el país para cada uno de los tratamientos y medicamentos comentados. Las opiniones vertidas en este programa son responsabilidad de los participantes o entrevistados, ScienceLink las ha incluido con fines educativos. Este material está dirigido a profesionales de la salud exclusivamente.

En esta cápsula de ESMO 2024 EXPRESS, el Dr. Santiago Viteri, oncólogo médico en UOMI Cancer Center de Barcelona, España, nos comenta brevemente las novedades presentadas durante el congreso que, a su parecer, son las más representativas en cáncer de pulmón. Estudio ALKOVE-1: Este estudio evalúa NVL-655. NVL-655 es un inhibidor de tirosina quinasa de cuarta generación específico para ALK, diseñado para evitar la inhibición de TRK, lo que mejora su tolerabilidad, especialmente en pacientes con metástasis cerebrales. El estudio mostró una tasa de respuesta objetiva del 38% en pacientes previamente tratados, destacándose una duración de respuesta de 14.4 meses en aquellos con mutaciones de resistencia ALK​. Estudio ARROS-1: Este estudio fase I-II evaluó zidesamtinib, un inhibidor específico para tumores con fusiones ROS1. Se observó una tasa de respuesta objetiva del 44% en pacientes con mutaciones de resistencia y metástasis cerebrales, mostrando respuestas intracraneales del 50% en los pacientes evaluados​. Estudio MARIPOSA-2: Este estudio fase III combina amivantamab con quimioterapia para pacientes con mutaciones de EGFR que han progresado tras tratamiento con osimertinib. Los datos preliminares sugieren una mejora en el tiempo hasta el siguiente tratamiento, aunque aún no hay significancia estadística en la supervivencia global​. Estudio REZILIENT1: Este ensayo evalúa zipalertinib, un inhibidor de EGFR específico para mutaciones del exón 20. Los resultados muestran una buena tasa de respuesta, con una mayor tolerabilidad comparada con otros inhibidores previos​. Fecha de grabación: 15 de septiembre de 2024

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available and emerging clinical data for second-line and beyond treatments in patients with recurrent ROS1-altered advanced NSCLC including:Assessing ROS1-TKI resistance mutations with tumor and liquid biopsies in patients with ROS1-altered advanced NSCLCPrevious TKI-treated cohort from the TRIDENT-1 study: efficacy of repotrectinib in patients with recurrent ROS1-altered NSCLC and measurable baseline brain metastases   Phase II TRUST-1 trial of taletrectinib: activity in patients with known ROS1 G2032R resistance mutation ROS1-altered advanced NSCLCThe global phase I/II ARROS-1 study of zidesamtinib (NVL-520): safety summary in patients with ROS1-altered advanced NSCLC  Program faculty:Jessica J. Lin, MDAttending PhysicianMassachusetts General HospitalAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsAlice T. Shaw, MD, PhDChief, Strategic PartnershipsAttending Physician, Thoracic OncologyDana-Farber Cancer InstituteHarvard Medical SchoolBoston, MassachusettsResources:To download the slides associated with this podcast discussion, please visit the program page.

In this podcast, we'll be talking and learning about Nuvola, a project focused on democratizing Decentralized Physical Infrastructure (DePIN). Today I'm join by Raul De Benedittis, Nuvola's co-founder & CEO. In this interview, we cover the Nuvola Drive, partnerships, catalyst proposals, business models, NVL token staking, revenue share models, and so much more! Stay tuned to learn more! -- Socials-- Website: https://crypto-loops.com/cardanoconvo/ Twitter: https://twitter.com/CardanoConvo Discord: https://discord.gg/atNKP2TUam  StakePool Site: https://www.crypto-loops.com/loops-pool/ StakePool Pool.pm: https://pool.pm/c9bc139d73045ba6c5b002ff88ea2a5854b3e783c468adb9250df917 -- Nuvola -- Nuvola Website: https://www.nuvoladigital.io/ Nuvola Twitter: https://x.com/NuvolaDigital Nuvola YouTube: https://www.youtube.com/@nuvoladigital Nuvola Medium: https://nuvoladigital.medium.com/ Nuvola Staking: https://app.nuvoladigital.io/ Nuvola Catalyst Proposal: https://cardano.ideascale.com/c/idea/120650 Nuvola Catalyst Tweet: https://x.com/NuvolaDigital/status/1803501900177793504 --Want to Help the Channel Out?-- Share on Twitter, Facebook, and other Socials! Delegate to LOOPS Stake Pool! ADA address: addr1qxjwn9huhcjurnztn8qp92y3j39xxjr224k78wlehashfg793m7fx6usftwtfhg9g53ddshhhssvpr859llf3w987gjqvpy37j

EP773 - Qual a diferença entre NVL, NULLIF e COALESCE | Podcast Oracle SQL   Entre no nosso canal do Telegram para receber conteúdos Exclusivos sobre Banco de dados Oracle:   https://t.me/joinchat/AAAAAEb7ufK-90djaVuR4Q

Jeff Samuels is an American professional beach volleyball player, entrepreneur and coach. A former lacrosse and hockey player, he fell in love with the beach and has been doing it full-time, ever since. Starting his career with the NVL, he won newcomer of the year. He has since won a slew of open tournaments, regionally and on big stages, and remains a top player on the tour. A spokesperson for Hyundai for various branches, he spends a ton of time doing clinics for juniors and sometimes adults. 02:30 - Huntington Beach, and Marcus Carvalhaes, winner's mentality, a path to tournament wins, 11:01 - Taking care to the mental, and how the mental affects the physical, taking care of things you can control 19:54 - Nutrition, good food habits, myth-busting the carnivore vs vegan, "Wagu" in his life, 34:29 - How Jeff hit the ground running as a competent juniors coach, speaking at "eye level," taking beats, the camps the clinics, Pre-Dino 43:18 - What do "be coachable" mean to you? Kloth and Nuss getting over the Brazilian "hump," plus, who do you trust with your juniors, collectively? 1:01:30 - Do people really WANT to put in the work in detail? To people overanalyze their approach? Are there really volleyball "secrets?" 1:12:56 - What in Volleyball should be 2 points, what rule are you glad is gone, plus, lightning rounds

John Moran was an American professional beach volleyball player. He has played with a slew of partners, and it seems that he has hit every possible stop the regionals and National scene has to offer. From the AVP to the NVL, to NORCECA, to the Motherlode, his prosperity at every level has been well-documented, which pales in comparison to how much he is well-loved by his contemporaries, fans and pundits alike. One can only speculate how he did this and a full-time job logistics and a start-up in a 24-hour day. 02:00 - The late-summer conditions of the last NVL tournament in Hermosa Beach 11:39 - Take advantage of opportunities with great players, good left-handed players, making your own greatness 18:55 - Hard work vs talent: do not be fooled by players that make it look easy, Rafu Rodriguez and Kevin McColloch 21:21 - The talent during the time he played in Arizona and the ridiculous perks 27:45 - Who is a good player flying under the radar a lot of people do not know (yet) 33:05 - Did Miles Partain force the domestic men's scene to get better? Will he take a break after 2024? 43:21 - Which US men's or women's team has the best shot at the Gold in Paris? 47:50 - The future of the AVP, and the "how," about training groups 1:01:44 - Professional beach volleyball: investment vs trust in the product, and the Dinosaur tournament, is traveling to stops worth it? 1:15:22 - Content creation vs viewership, enlisting the best people for the positions 1:32:13 - About coach Placek 1:34:52 - Lightning Round

Ecco a voi l'ultimissima puntata prima delle vacanze natalizie per augurarvi buon natale e buone feste e grazie per la compagnia e la stima che ci dimostrate ascoltandoci. mille volte GRAZIE! Buone Feste!

Ecco a voi una nuova puntata di dance! si balla 2.0buon ascolto

Ed eccoci, cari amici di radio32, con il nostro Diego Mariani, mitico cultore musicale, che ci propone della ottima musica d'annata doc. A voi.

Gabriele Attadia presenta: Dance si balla! 2.0 con l'aggiunta di tutta la ciurma di NewVoicesLab, novità assoluta per le nuove puntate. Con Alessio Federici, Valentina Lelli, Martina Pasquali, Francesco D'Ascanio e Gabriele Attadia. Buon ascolto.

Torna come ogni lunedì l'appuntamento con la musica del nostro Diego Mariani. Buon ascolto!

Torna il nostro mitico Diego Mariani e la sua musica del cuore che ci propone con pillole di sapere non indifferente che ci aiuta a degustarla. Buon lunedì

We've reached the penultimate week of the 2023 regular season, the week where we set the Thanksgiving table and learn, definitively, who is in and who needs what to qualify for the CIAC playoffs.  And, yes, your crack staff at GameTimeCT hunkered down with our slide rules and abacuses this weekend so that we may give you our best estimates on the latest scenarios heading into the final week and a half.  We also run down the latest top 10 poll and recap some of last week's big games, beginning with No. 9 Ansonia's 35-0 takedown of Oxford in an unbeaten NVL battle at Jarvis Stadium last week in, perhaps, a harbinger of playoff matchups to come.  We also recap the return of North Haven coach Tony Sagnella from his weekend suspension and sift through the ongoing soap opera in Monroe, where Masuk's seniors have risen about the controversy surrounding their coaching staff, to deliver an emphatic, playoff-qualifying victory over New Milford.  Don't miss our weekly shoutouts and a look at the upcoming NEPSAC Bowl championship games.  So join us, won't you? RUNDOWN 0:00 — Introduction 3:34 — Ansonia knocks off unbeaten Oxford, heads into Thanksgiving 9-0 9:42 — Week 11 GameTimeCT Top 10 Football Poll (Nos. 10-7) 11:38 — Sagnella returns from suspension for No. 6 North Haven 12:49 — Week 11 GameTimeCT Top 10 Football Poll (Nos. 5-1) 14:53 — 2023 Playoff Scenarios: Explaining CIAC's playoff formula and website issues 19:45 — Class S Playoff Scenarios (North Branford's huge win)  22:38 — Class SS Playoff Scenarios  25:16 — Class M Playoff Scenarios 26:35 — Class MM Playoff Scenarios (Cheshire in trouble) 32:22 — Class L Playoff Scenarios 34:22 — Class LL Playoff Scenarios (Can Fairfield Prep pull this off??) 43:20 — Seniors rise above the mess at Masuk 54:42 — SHOUTOUTS 1:03:43 — Suffield Academy upsets Cheshire Academy, NEPSAC Bowl matchups announced Learn more about your ad choices. Visit megaphone.fm/adchoices

Bentrovati amici di radio32.net. Anche oggi, lunedì 13 novembe, il nostro diego mariani ci tiene compagnia con la sua musica del cuore. Buon ascolto

We knew it was coming and here it is. The Alliance brass has interrupted the season with their latest call to remove Thanksgiving Day as Connecticut's crown jewel of sporting events. The idea: Dump a century's worth tradition in favor of a balanaced schedule based on class, 50% more (whyyy??) playoff teams, the ending the season before the wrestling mats get rolled out. A win for 12 schools' winter programs and 24 middling football teams, perhaps. Naturally, our intrepid podcast hosts have their own opinions on this latest move to remove Thanksgiving Day football, and they lay out their pros and cons of this budding tradition of yearly CT high school football playoff ideas. This week's special guest star is none other than JOE STOCHMAL, the only coach Oxford's ever known. His program is 8-0 for the first time and on pace to reach the state playoffs for the first time, even as they head to Jarvis Stadium to face unbeaten NVL rival Ansonia on Thursday night.  Stox gives us the lowdown on his program and, as a member of the CIAC football committee, shows us the roadmap on how playoff proposals become CIAC law. He also gives us his personal opinion on the Alliance proposal.  In the meantime, check out highights from a handful of Week 9's biggest games, including: No. 3 Maloney rallying past Southington; North Haven, sans coach Tony Sagnella, knocking off Matt Jeffery-less No. 2 Cheshire; and, finally, Choate's 17-14 victory over Avon Old Farms in the most anticipated Prep school game of the year, since last year. It's a jam-packed and long episode. But, with this last full week of non-Thanksgiving football, why not spread our wings a bit? So join us, won't you? RUNDOWN  0:00 — Introduction. 2:00 — Turkey Day games in September?? No, Thanks: The Alliance playoff proposal. 20:07 — The Week 10 GameTimeCT Top 10 Poll (Nos. 10-8) 21:30 — Sagnella-less North Haven takes out Jeffery-less No. 2 Cheshire 28:33 — GTCT Top 10 Poll (Nos. 5-1) 29:55 — No. 3 Maloney rallies, holds off Southington 37:09 — Bunnell knocks off Notre Dame-Fairfield 38:27 — CLASS S playoff update:  39:40 — CLASS SS playoff update:  41:44 — CLASS M playoff update:  44:19 — CLASS MM playoff update:  46:36 — CLASS L playoff update 48:28 — CLASS LL playoff update 54:34 — Interview with OXFORD coach JOE STOCHMAL 1:31:24 — Shoutouts! 1:38:40 — Choate beats Avon Old Farms in anticipated NEPSAC unbeaten showdown 1:46:07 — Wrapping up Learn more about your ad choices. Visit megaphone.fm/adchoices

Week 5 is upon us and to celebrate we have not one but two great guests this week as Benny from the block & fan favourite Chris Milner from the NVL joins Nat to preview the games & also chat a bit of daily fantasy. The guys start though with the slate on Sunday & each pick the game they are most excited about inc. Texans/Falcons, Bills/Jags & Cowboys/49ers before focusing on the teams that everyone should be concerned about for the rest of the season & you won't want to miss this as Nat goes on a 4 minute monologue about the Pats. If this wasn't enough Chris picks a fantastic show team for the Draft Kings listener league & of course we have the 57 seconds challenge as well! Check out the brilliant National Vintage League website for some sensational vintage items: https://nationalvintageleague.com/ You can enter your own team for free by signing up to DraftKings (dkng.co/NatCoombsShow) and using the promo code NC Show. Each week we have free to enter contests with prizes courtesy of DraftKings and USA Sports! 18+ Be Gamble Aware. The highest score from the first 3 weeks gets the tickets so make sure you enter your team!  Play against your show faves in our Draft Kings listener league where you can win merchandise & tickets - https://www.draftkings.co.uk/leagues/nfrs2hi8/contests/upcoming - Eligibility Restrictions Apply. See website for details. 18+ only. www.BegambleAware.org® The Nat Coombs Show is proudly partnered by USA Sports: the best place to buy all of your American sports merch this side of the pond. From football, hockey, basketball, baseball and much more - there's something for everyone! Rep your favourite teams and get 20% off your order using discount code ‘NCSHOW' today. USA Sports merch for the fans, by the fans. Check out USA Sports: https://www.usasports.co.uk/ Subscribe to our Brand New YouTube channel for loads of video and bonus footage from the show - https://www.youtube.com/@TheNCShow Other show socials: Twitter: https://twitter.com/thencshow Facebook: https://www.facebook.com/thencshow Instagram: https://www.instagram.com/thencshow/ Tik Tok: https://www.tiktok.com/@thencshow?lang=en Threads: https://www.threads.net/@thencshow

Nat & Ben get into all latest from across the NFL including the sale of the Commanders, the Saquon dilemma and the Lions new WR before Ben looks ahead at the 2024 Draft and names his Top 3 Receivers that he predicts will go first round. The boys look ahead to the Notre Dame/Navy game in Dublin - Road Trip!- and are joined by friend of the show Chris Milner of NVL fame who nominates his fave football movie into The NC Show HOF. In association with our great friends at College Football Ireland - https://collegefootballireland.com/ Join Nat, Ben and lots of your show faves and NC Show fam in our listener league. Win prizes each week, including merch and NFL UK tickets. Eligibility Restrictions Apply. See website for details. 18+ only. www.BegambleAware.org®

Die Diagnose "Diabetes Typ 2" wird vor allem in der Hausarztpraxis gestellt. Die Aktualisierung der Nationalen Versorgungsleitlinie (NVL) trägt dem Rechnung. Dr. med. Kai Florian Mehrländer ist Koautor der NVL und selbst Hausarzt. Im Gespräch erklärt er, welche Änderungen sich durch das Update im Praxisalltag ergeben und wie eine wertschätzende Kommunikation mit Betroffenen gelingt.

 - Quý I, thành phố Đà Nẵng cấp mới 28 dự án FDI với tổng vốn đầu tư đăng ký gần 4,5 triệu USD- Khánh Hòa: Chỉ số PCI tăng 28 bậc- Phiên chứng khoán chiều qua, cổ phiếu NVL "đắt khách", VN-Index giữ sắc xanh Chủ đề : chứng khoán, sách xanh --- Support this podcast: https://podcasters.spotify.com/pod/show/vov1kd/support

NVL CÓ ĐỔ NỢ? RỦI RO VỚI TRÁI PHIẾU BĐS? LIỆU CÓ CON ĐƯỜNG SÁNG? Nhiều bạn hữu cho rằng NVL đã “lột xác” từ blue-chip thành penny, vậy áp lực từ NVL lên thị trường bất động sản và hệ thống các ngân hàng là gì? Chúng ta sẽ phân tích chi tiết đến từng con số dựa trên báo cáo tài chính gốc của NVL, các báo cáo phân tích NVL cùng phần mềm Kungfu Stocks Pro,... và xem liệu có con đường sáng nào dành cho NVL không nhé bạn hữu.

We have show debut for the brilliant comedian, NFL expert, entrepreneur & Channel 5 broadcaster Chris Milner! Nat & Chris discuss Chris' route into the NFL & how he set up the brilliant NVL (2:30), Baker's move to LA (25:30), his love for Washington and how it came about (31:30), the NFC East race (38:40), Detroit's playoff chances (43:30), the Mike White v Zach Wilson debate (47:00) + much, much more.  National Vintage League Website: https://nationalvintageleague.com/ Think you know your football? Join our NC Show listener league on Draft Kings and play daily fantasy each week! Go up against Nat, Prop O, The Guru Sandrini & more of your show faves, pick a brand new team every week, win prizes....and the respect of your peers! Free to enter contest will feature throughout the season too! League Contests: http://dkng.co/NatCoombsShow DraftKings Contests: https://dkng.co/DKContests Follow the fellas on twitter:  Nat Coombs: https://twitter.com/NatCoombs National Vintage League: https://twitter.com/NVLTweets

Last week marked FIVE STRAIGHT YEARS OF SANDCAST! In five years, somehow, Tri Bourne and Travis Mewhirter haven't missed a single episode. So much has happened: - Travis made his first AVP main draw (then a bunch of international medals) - Tri battled an autoimmune disease...then became an Olympian...then a two-time Manhattan Beach Open champion - Tri had a kid, Naia Bourne, who makes many appearances on this episode - Travis got married to Delaney Knudsen, who has since won a bunch of big time matches and tournaments, including the USA Volleyball Queen of the Beach - Gabby Bourne produced her own movie, and is soon appearing in one with Ben Affleck and Matt Damon (!!!) - Our numbers have exploded, growing, on average, 30 percent per year - The NVL came and went - p1440 came and went - Volleyball World became a thing - The AVP was bought by Bally's - And a whole, whole lot more. We just got the full family together on this one and reflected on five years of podcasting, and the wild and surreal life changes that have come with it. Thank you all SO MUCH for being part of this wonderful journey. Cheers to five years, and cheers to five more SHOOTS! *** NEW BOOK ALERT!!! Travis Mewhirter and Kent Steffes just published a seminal work on the history of beach volleyball in their new book, Kings of Summer: The Rise of Beach Volleyball. Check it out on Amazon!! https://www.amazon.com/Kings-Summer-rise-beach-volleyball/dp/B0B3JHFKM7/ref=sr_1_1?crid=1WGJFWHPBGPQ2&keywords=kings+of+summer+book&qid=1658922972&sprefix=kings+of+summer+book%2Caps%2C1328&sr=8-1 We are FIRED UP to announce that we've signed on for another year with Athletic Greens! Stay healthy with Tri Bourne and Travis Mewhirter and get your greens today! https://athleticgreens.com/partner/d35ctoffer-strength/en?utm_source=podcast&utm_medium=influencer&utm_campaign=sandcast_d35ct__a3172__o27&utm_term=cac__a3172__o27&utm_content=sport__a3172__o27 We now have SANDCAST MERCHANDISE!! Rock the gear of your favorite podcast today! https://www.sandcastmerch.com/ If you want to receive our SANDCAST weekly newsletter, the Beach Volleyball Digest, which dishes all the biggest news in beach volleyball in one quick newsletter, head over to our website and subscribe! We'd love to have ya! https://www.sandcastvolleyball.com/ This episode, as always, is brought to you by Wilson Volleyball, makers of the absolute best balls in the game, hands down. You can get a 20-percent discount using our code, SANDCAST-20! https://www.wilson.com/en-us/volleyball Check out our book, Volleyball for Milkshakes, written by SANDCAST hosts Tri Bourne and Travis Mewhirter: https://www.amazon.com/Volleyball-Milkshakes-Travis-Mewhirter/dp/B089781SHB  

Welcome back to another edition of The Meat Grinder, your weekly inside look at high school football in Connecticut with GameTimeCT's Pete Paguaga and Sean Patrick Bowley. It was the Weekend of the Living Dead, in which a bunch of teams across the state got an early Halloween scare. Pete and SPB talk all about the great NVL showcase game won by Holy Cross rallying past Naugatuck on Thursday, plus East Hartford and Newington scares vs. No. 1 Southington and No. 3 Maloney, respectively. SPB also breaks down his trip to Granby Memorial for Cromwell/Portland's 14-7 victory and, his hectic Prep school Saturday, capped by the insane Avon Old Farms comeback that fell one agonizing point short against Choate in Saturday's NEPSAC showdown. Joining us for a chat this week is Killingly's 18-year head coach Chad Neal, who enjoyed a nice weekend off, but now gets back to business as he and his players get ready for a showdown with unbeaten Windham on Friday night. Coach Neal discusses this year's No. 4-ranked squad, and what it took to get his program playing at a championship level after a good 10-year struggle.

Welcome back to another edition of the Meat Grinder, your weekly inside look at high school football in Connecticut with Pete Paguaga and Sean Patrick Bowley. If Week 4 was the Alliance Love Fest, Week 5 was the return of the jilted lover, our forgotten friend, the league game. We start in the SCC where Hamden took out Fairfield Prep for the first time since 2009 and North Haven dropped No. 3 Shelton for its first win over the Gaels since 1994. In the NVL, Gilbert/Northwestern/Housy put a scare into Ansonia; Staples outlasted Trumbull in an FCIAC thriller; Berlin rallied to beat Bloomfield in the CCC and so much more. Though the SCC, FCIAC and SWC have bye weeks, league play continues this week. Chris Anderson, a two-time championship coach at Woodland and now the head coach at Naugatuck, joins us this week to discuss his league's big game against Tom Ligi and Holy Cross at Municipal Stadium on Thursday night. Anderson, now in his second year in command of the Valley powerhouse, gives us his take on the matchup and a look at his team as it attempts to repeat last year's successful run to the NVL championship and state playoffs. So join us, won't you? Listen to the Meat Grinder now on your favorite streaming service, but sure to check out the Live Action version of the show on Tuesday evenings.

Jeff Samuels is an American professional beach volleyball player, entrepreneur and coach. A former lacrosse and hockey player, he fell in love with the beach and has been doing it full-time, ever since. Starting his career with the NVL, he won newcomer of the year. He has since won a slew of open tournaments, regionally and on big stages, and remains a top player on the tour. A spokesperson for Hyundai for various branches, he spends a ton of time doing clinics for juniors and sometimes adults. David "Doc" Vander Meer is an American beach volleyball player. A defensive standout at Ball State university on the indoor scene, he quickly took his talents to the beach, where he remains a top player on the beach scene. His fifth-place finish in Atlanta a year ago was highlighted by upsetting the number one seed Dahlhauser and Lucena. Tune in, as we chat up "hands," chatting up with special guest, ref Dave Carson, the NCAA 16 team format, what we miss/not miss about the freeze, venues we would like the AVP to come back to, lighting rounds, taking care of your body, Phil's greatness, Doc's Atlanta upset, the best players on the world and domestic scene, advice to the next generation of male players, and MORE!

How do you stay motivated to train hard? Learn how to make your volleyball experience the most rewarding one by getting a coach who knows exactly what you need to work on. It contains powerful words of wisdom that will help you to coach your players effectively. Check this out as Coach Abra Rummel shares her "WOW" (Words of Wisdom) in volleyball coaching!

Want to be the BEST? Beach volleyball coaches don't want you to just play volleyball, they want you to play BETTER volleyball. They want to win and have a good time doing it. That is why we are here—to develop winning habits for players of all skill levels. Give us a SHOUT out in today's episode with Coach Mark Burik and Coach Gretchen Hand. Learn how we can help you make your beach volleyball experience the BEST!

Key Points, Top Takeaways, and Memorable Quotes “It's a blessing and a curse.  It just depends on how you harness it and you make it work for you.” 7:06“Man, when I make money, I'm going to wear whatever I want.” 13:09“I'm able to teach them what I've learned and what I wish I would've learned.” 22:01“Hate is a powerful tool.” 36:17“You can't ask ‘what if?' So you just go with what you got and push forward.  Let's not ask what if, let's find out what can we do?” 55:36“Get a journal.” 1:08:26“This is  where my wife comes in. She has shown she loved me and showed me love like no one has.” 1:25:05“I forgive you for what you've done.  What you did to me or what you did to anybody or what anybody has done to me is not going to delegate what I do in the future.” 1:31:44“I started to realize we're energy in a sense, and we've only got so much energy throughout the 24 hours that we are given. You can invest and give your energy to things that aren't going to grow and produce and flourish or you can put your energy towards the things that are going to make a difference, grow, mature, and make whoever you're giving it to a better person.” 1:34:03“If you can push it, push it.” 1:55:39“I don't tell anybody good luck anymore.  I tell them ‘Go do your best.'” 2:01:21Guest Bio - Shawn Ledig is a Louisiana native and athlete for life who uses every bit of what he has learned on the court and the mat to become a better human and set an amazing example for the next generation.  From humble beginnings to college basketball, professional beach volleyball, to  becoming a World Champion in jiu-jitsu at age 46, to being a husband, husband, father, son, and friend…not to mention a structural engineer and small business owner, Shawn is here not just to level up his own game, but inspire others to do the same. Show Notes0:20 - Intro1:27 - Where do you come from?1:48 - Hawaii and Louisiana Roots3:04 - Step Dad: the Good and Bad of a rocky relationship6:12 - Early Sports Experiences7:51 - Nostalgia of Home8:38 - Influence of Working for Christian Private School9:20 - Advocating for myself to make the basketball team11:04 - Being a discipline problem for my single mom13:58 - the experience of growing pains16:13 - Race and basketball - I was the only white guy on the team18:03 - My Dad and I Didn't See Eye to Eye18:25 - Senior Year: Starting A Dynasty20:10 - Thank God for My Coaches22:44 - from an Ankle Injury to a Modeling career  to a degree in Engineering24:45 - Never Touched A Volleyball Until Coconut Beach27:55 - Falling in love with Beach Volleyball 30:04 - NVL in Dallas32:40 - California Livin' or No?34:53 - How Sports Broke the Abuse Pattern36:38 - The Last Time My Dad Abused My Mom41:55 - Nightlife in the French Quarter43:06 - The Mask From the Movie44:53 - Kissing Lindsay Lohan48:10 - Dance Moves51:30 - First born - Seth's Birth Changed Me54:07 - NVL Hermosa Beach Behind the Mic Together56:16 - Can the Big Guy Set?57:28 - NVL Ohio and the Skills Nazis59:30 - They All Knew I Was Green1:00:35 - Consistent Competition: Iron Sharpens Iron1:03:30 - It's All Built My Character1:04:06 - Jujitsu Peaked My Interest1:06:38 - Look At Those Bad Boys Back There1:07:26 - I Want to be Number One at European Championships1:09:26 - Body types - Were You Skinny as a Kid?1:11:57 - The Brain Only Moves So Fast1:17:55 - Competition Weight is a Mental Thing1:23:00 - Organized Coaching1:23:48 - Road to Rome Interview1:24:50 - Finding Ways to Break the Cycle1:26:33 - My Dad's Real Family1:32:04 - Hate is Your Character Armor1:33:53 - We're Energy1:34:30 - Second Guessing1:35:15 - Volleyball As A Release1:35:45 - Body and Brain Connection: Gut Health1:37:16 - Overcoming Energy Vampires1:42:32 - The World's Story About Men and Women1:43:26 - Jason's Story About Kenny1:45:00 - AVP Talk1:51:51 - What Does Shawn Expect From the AVP Tour?1:54:22 - Some Athletes Are Warriors1:56:10 - Next Month at Coconut Beach1:56:47 - AVP Next Gold Tour Series New Orleans Clip1:59:10 - Two Big Tournaments Back to Back2:00:00 - Coaching A Girl or Two at Coconut Beach2:00:35 - Real Life Calls2:01:57 - What Keeps Me Going2:04:20 - Talking Meat and Vitamin C2:06:40 - Off the Record Dialogue2:08:53 - Wrap Up Links & Where to Find Shaun IG - @rome_wasnt.built_in_a_dayFB - Shawn Ledig Links & Where to Find Jason The Option Podcast streaming on all the platformsIG - jdibeliusFB - Jason Dibelius & NY Varsity Sports

Key Points, Top Takeaways and Memorable Quotes “It's a blessing and a curse.  It just depends on how you harness it and you make it work for you.” 7:06“Man, when I make money, I'm going to wear whatever I want.” 13:09“I'm able to teach them what I've learned and what I wish I would've learned.” 22:01“Hate is a powerful tool.” 36:17“You can't ask ‘what if?' So you just go with what you got and push forward.  Let's not ask what if, let's find out what can we do?” 55:36“Get a journal.” 1:08:26“This is  where my wife comes in. She has shown she loved me and showed me love like no one has.” 1:25:05“I forgive you for what you've done.  What you did to me or what you did to anybody or what anybody has done to me is not going to delegate what I do in the future.” 1:31:44“I started to realize we're energy in a sense and we've only got so much energy throughout the 24 hours that we are given. You can invest and give your energy to things that aren't going to grow and produce and flourish or you can put your energy towards the things that are going to make a difference, grow, mature, and make whoever you're giving it to a better person.” 1:34:03“If you can push it, push it.” 1:55:39“I don't tell anybody good luck anymore.  I tell them ‘Go do your best.'” 2:01:21Guest Bio - Shawn Ledig is a Louisiana native and athlete for life who uses every bit of what he has learned on the court and the mat to become a better human and set an amazing example for the next generation.  From humble beginnings, to college basketball, professional beach volleyball, to  becoming a World Champion in jiu jitsu at age 46, to being a husband, husband, father, son, and friend…not to mention a structural engineer and small business owner, Shawn is here not just to level up his own game, but inspire others to do the same.Show Notes 0:20 - Intro1:27 - Where do you come from?1:48 - Hawaii and Louisiana Roots3:04 - Step Dad: the Good and Bad of a rocky relationship6:12 - Early Sports Experiences7:51 - Nostalgia of Home8:38 - Influence of Working for Christian Private School9:20 - Advocating for myself to make the basketball team11:04 - Being a discipline problem for my single mom13:58 - the experience of growing pains16:13 - Race and basketball - I was the only white guy on the team18:03 - My Dad and I Didn't See Eye to Eye18:25 - Senior Year: Starting A Dynasty20:10 - Thank God for My Coaches22:44 - from an Ankle Injury to a Modeling career  to a degree in Engineering24:45 - Never Touched A Volleyball Until Coconut Beach27:55 - Falling in love with Beach Volleyball 30:04 - NVL in Dallas32:40 - California Livin' or No?34:53 - How Sports Broke the Abuse Pattern36:38 - The Last Time My Dad Abused My Mom41:55 - Nightlife in the French Quarter43:06 - The Mask From the Movie44:53 - Kissing Lindsay Lohan48:10 - Dance Moves51:30 - First born - Seth's Birth Changed Me54:07 - NVL Hermosa Beach Behind the Mic Together56:16 - Can the Big Guy Set?57:28 - NVL Ohio and the Skills Nazis59:30 - They All Knew I Was Green1:00:35 - Consistent Competition: Iron Sharpens Iron1:02:39 - Or Relationships? Hint Hint: Savvy Simo1:03:30 - It's All Built My Character1:04:06 - Jujitsu Peaked My Interest1:06:38 - Look At Those Bad Boys Back There1:07:26 - I Want to be Number One at European Championships1:09:26 - Body types - Were You Skinny as a Kid?1:11:57 - The Brain Only Moves So Fast1:17:55 - Competition Weight is a Mental Thing1:23:00 - Organized Coaching1:23:48 - Road to Rome Interview1:24:50 - Finding Ways to Break the Cycle1:26:33 - My Dad's Real Family1:32:04 - Hate is Your Character Armor1:33:53 - We're Energy1:34:30 - Second Guessing1:35:15 - Volleyball As A Release1:35:45 - Body and Brain Connection: Gut Health1:37:16 - Overcoming Energy Vampires1:42:32 - The World's Story About Men and Women1:43:26 - Jason's Story About Kenny1:45:00 - AVP Talk1:51:51 - What Does Shawn Expect From the AVP Tour?1:54:22 - Some Athletes Are Warriors1:56:10 - Next Month at Coconut Beach1:56:47 - AVP Next Gold Tour Series New Orleans Clip1:59:10 - Two Big Tournaments Back to Back2:00:00 - Coaching A Girl or Two at Coconut Beach2:00:35 - Real Life Calls2:01:57 - What Keeps Me Going2:04:20 - Talking Meat and Vitamin C2:06:40 - Off the Record Dialogue2:08:53 - Wrap Up Links & Where to Find Shaun IG - @rome_wasnt.built_in_a_dayFB - Shawn Ledig Links & Where to Find Jason The Option Podcast streaming on all the platformsIG - jdibeliusFB - Jason Dibelius & NY Varsity Sports

Jeff Samuels is an American professional beach volleyball player, entrepreneur and coach. A former lacrosse and hockey player, he fell in love with the beach and has been doing it full-time, ever since. Starting his career with the NVL, he won newcomer of the year. He has since won a slew of open tournaments, regionally and on big stages, and remains a top player on the tour. A spokesperson for Hyundai for various branches, he spends a ton of time doing clinics for juniors and sometimes adults. Tune in, as we chat up, the introduction of the flagrant foul in the NBA, the Will Smith controversy, when words matter and when they do not, respect vs healthy fear in and out of sports, talking to juniors about being careful with the "South Bay stare," knowing who someone is vs highlighting their worst moments, positive reinforcement vs tough love, understanding oppositional defiance disorder, not making moments bigger than they are on court, game-based drills, vs non-game based drills, self-examination leading to self-correction, knowing when to ask for help and humbly accepting it, "respect on one's name," how rule changes rarely affect the top players in the world, players who have to allow coaches to help them, and MORE!

This is Part 2 of Matt's interview with Chris Milner of National Vintage League. If you haven't checked out Part 1, go do that! Here's some info on NVL: National Vintage League is a British-based retro apparel company that started out specializing in NFL jackets and jerseys but has since expanded into selling NHL, MLB, NCAA and all your favorite sports leagues. Initially founded by Hugh Coles in 2017, Chris joined the company in 2018 and was kind of enough to sit down with Matt to discuss the company's origins, how he became a fan of the NFL and more! Also check out NVL's podcast, The National Vintage League Show! Note: unfortunately, Hugh could not make the show but hopefully we can have both of them back on the show soon!

Been awhile since the last interview and it was an absolute pleasure to have Chis Milner from National Vintage League on the show. National Vintage League is a British-based retro apparel company that started out specializing in NFL jackets and jerseys but has since expanded into selling NHL, MLB, NCAA and all your favorite sports leagues. Initially founded by Hugh Coles in 2017, Chris joined the company in 2018 and was kind of enough to sit down with Matt to discuss the company's origins, how he became a fan of the NFL and more! Also check out NVL's podcast, The National Vintage League Show! Note: unfortunately, Hugh could not make the show but hopefully we can have both of them back on the show soon!

It's the Thursday that all the die-hard NVL fans have been waiting for, because in this episode we sit down with NVL legend & former San Diego Chargers quarterback - Ryan Leaf. We talk about who was hosting SNL the night he didn't win the Heisman, his encounter with a literal "basket case" female admirer, the story behind THAT interview, and end as ever with our stupid game - this week it's "Let's Get Niche With Ryan Leaf" New episodes every Thursday! SHOP WITH US: www.nationalvintageleague.com

Don't let these Witts fool you, with their Colgate smiles and constant giggles and impossibly amiable personalities. Then again, how could you not be fooled? Was that McKenna in the Oakleys or Madison? Wasn't McKenna on the right? Or did they switch? Hold on…it was Madison with the 4-centimeter tear in her ab…right? Or was that the other one, the one who looks just like her, down to the cascade of dirty blonde hair and almond-shaped eyes and what they call “twig-noodle” frames? Kerri Walsh couldn't figure it out when she played the Witts in 2016. Neither could their high school teachers on the one occasion they swapped places in math and Spanish, though so overwhelming was their guilt and nerves that they never did it again. “I was so nervous,” McKenna Witt, now McKenna Thibodeau, said. Yes, the Witt sisters are technically no longer. McKenna is now a Thibodeau, and Madison, recently engaged, will soon become a Willis. The Thibodeau-Willis sisters don't exactly have the same ring as the Witt Sisters. No matter. They still have the same identical looks, despite an NVL official once attempting to change that, marking Madison with a No. 1. Or hold on. Was that McKenna? Not that it mattered. She washed it off anyway. McKenna had a tear in her ab, and she wasn't going to be picked on. Beyond that, Madison wasn't going to let another team complain about playing a pair of identical twins, especially when one of them is injured, and exposing which one that was could mean furthering the injury. Simply put: You don't mess with a Witt, and you certainly don't mess with one when the other is on the same court. “We're fierce competitors,” Madison said,. Killers with a smile. So hungry for success are they that in less than five years playing beach volleyball they've become All-Americans, finished their four years at Arizona with an 85-33 record, qualified for an AVP in San Francisco in 2016, grinded through an NVL qualifier in 2017 and advanced to the semifinals, picked up their Masters degrees doing a grad year indoors with Cal Baptist all the while planning McKenna's wedding. Now they're the poster girls for P1440, selected as one of the tour's developmental teams. It appears to have been a smooth ride for the Witts. Little turbulence, few setbacks, the American Dream from a pair of sisters who are as likable as they are marketable. Their path has been quite the contrary, and they like it that way. They love telling the story about how they were cut from their seventh-grade team, touching a ball for the first time in an organized setting in eighth grade. They aren't necessarily enamored with their 13-15 record at Arizona as freshmen, but they're able to look back upon it with fondness, for prior to the season, they had to relearn how to throw a ball, let alone hit one. They're not kidding, either. Their coach, Steve Walker, didn't like how they threw a ball, which replicates the mechanics for an arm swing. So in their first week as collegiate beach volleyball players...they threw volleyballs. “Looking back, we loved the process,” Madison said. “Steve would always say ‘Rome isn't built in a day' and man is that true… The process is beautiful. You don't grow on mountaintops.” They didn't. And their steep growth created a style they refer to as “scrappy, weird athletic, and fun.” The weird athletic can be up for interpretation. The fun part is not. They're contagious, these Witts, forever smiling, laughter providing the soundtrack to their conversations, humble from an upbringing ground in faith. “We'll do whatever is takes to win,” McKenna said. “But we'll still be nice.”

It's not a tour. That's the first thing that Dave Mays, this week's guest on SANDCAST: Beach Volleyball with Tri Bourne and Travis Mewhirter, wants you to know about p1440, of which he is a founding partner. It is many different things with many different meanings. Take, for example, the name itself. The 1440 is assured: It represents the 1,440 minutes we all have per day. But the p? Platform seems to be the most popular word for it, though, as Mays says, it's up to your own interpretation. It could be purpose. Or power. Or people. Or whatever word that starts with ‘p' you'd like to use to represent how you'd like to use your 1,440 minutes in a day. Would you like to use it to strengthen your relationship with people? People it is. Or strengthening your mind, body and soul? Power it is. That sort of the point: p1440, and how you spend your minutes, is up to you. To some, yes, that means it's a beach volleyball tour or league, and currently, there are eight events on the schedule, which bridges 2018 and 2019. The first four are set – Chicago in September, with Huntington Beach, San Diego and San Jose to follow – while the next four, which will be held in early 2019, are in limbo, though the sites have been whittled down to a few catchy options. There's Vegas – Vegas! – a major city in Texas (Dallas and Houston, namely), Miami, Hawaii. An ambitious start. An exciting start. And that hardly scratches the surface, for each event is not just a beach volleyball tournament. It is, as Kerri Walsh-Jennings, a co-founder along with her husband, Casey Jennings, and Mays, has taken to saying: “Part Wanderlust, part Coachella, part beach volleyball league.” Each event, tantamount to the World Series of Beach Volleyball, will feature a tournament, but it will also serve as a music festival of sorts, replete with concerts and fanfare and everything you'd expect of the triumvirate Walsh-Jennings mentioned. How, you may be wondering, can an upstart tour fund eight events while also doubling as a music festival? Beach volleyball has been a notoriously volatile space in the market, in spite of the sport itself growing every year, to the point that more girls play volleyball than soccer or track and field or basketball. For females, it's the most popular sport in the country. And yet nobody has been able to monetize the market in a sustainable enough fashion for it to work. The business model has remained the same since a company named Event Concepts began putting on professional events in 1976. They'd find a sponsor – Schlitz Beer was the first – or many sponsors, to throw in money, and that money would then be translated into prize money, which would draw talent and a crowd to watch that talent. Sponsors would be happy because they got the eyeballs they wanted, players would be happy because they got the prize money they wanted. And so it went. Until, of course, the tabs being run up by the tour were too hefty for the sponsors to cover, and one gigantic failure led to the next. Event Concepts was booted in 1984, thanks to a player protest at the World Championships of Beach Volleyball, and in came the AVP, an organization led by the players and a young, savvy agent named Leonard Armato. The AVP changed hands in 1990, when Armato was replaced by Jeff Dankworth, who in 1994 was replaced by Jerry Solomon, whose gross mishandling of the finances led to a bankruptcy, only for the AVP to be revived by – who else? – Armato in 2001. Nine years later it was bankrupt again, and in 2012, Donald Sun took over and put on a pair of events, and since then he has done a fine job of steadying the frighteningly tenuous heartbeat of beach volleyball, increasing prize money and events and introducing a “Gold Series” and putting the sport back on television. And yet the business model remains relatively the same, though there are certainly various nuances, as 1976: sponsor-driven. “If we were to start a new pro beach volleyball tour tomorrow, we would fail,” Mays says on SANDCAST. “So that's why we're not starting a pro beach volleyball tour. We're taking the sport of volleyball and we're celebrating it, what works and what doesn't. We're applying some principles of what have worked and what do work, to this.” And here is where the differentiation between p1440 and the AVP Tour begins. p1440 will charge a $40 gate fee, every tournament. The AVP allows its fans, which pack stadiums, for free, though there are paid box seats. But the entry gate will hardly be the chief source of revenue for p1440. That's where the “platform” comes in. Above all else, above volleyball and music and entertainment, p1440 is built upon four pillars: competition, development, health and wellness, entertainment. The platform, an online resource featuring myriad digital media, will host webinars, coaching, nutrition, live clinics – any type of wellness resource you might need, be it mental, spiritual or physical. It's not live yet – it is scheduled to launch in July – and until 2021, it will not be monetized. The content will be entirely free, with the goal of reaching 4 million subscribers by 2021, by which point a subscription fee will be required. No numbers are for sure in terms of the subscription fee, but on SANDCAST, there was a $5 estimate. If p1440 hits its goal of 4 million subscribers at $5 a month, you can do the math – $20 million in revenue per month from the platform alone. If successful – an admittedly large “if” in this sport – the subscription model answers, in part, where the prize money and funding for the tour will stem from. Which leads to the next inevitable question: Who will be receiving those paychecks? Mays, who built and sold a shipping business for a not-so-small fortune and was looking for a new project to work on, thinks it's no question at all: p1440 will feature the finest talent in beach volleyball, and not only because there will be more prize money – he gave no definitive figure on what the breakdown will be, only that it will be more – but there will be more talent. The failure to retain the game's highest talent led to the breakdown of the NVL. Players want to play against the best, which was why, when Sun revived the AVP in 2012, and the top players returned, the NVL lost momentum and, eventually, financial backing. The best currently play on the AVP and FIVB tours. There will be a battle over loyalty, the AVP's non-compete (p1440 has no exclusivity clause in its contract), and, when it comes down to it, prize money and sponsors. Mays intends on bringing in the best, not only in this country, but overseas. Each tournament will feature a 24-team main draw. Sixteen of those teams will be Americans automatically seeded in. Four will come out of the qualifier. And four will be international wild cards. Want to play against the best? p1440 could have Alison and Bruno, or Evandro and Andre, or Nicolai and Lupo. For the women, it could be Ludwig and Walkenhorst, Agatha and Duda, Talita and Larissa. Walsh's reach, even if she has been on the peripherals of the game as a player lately, is still extensive. You don't win three gold medals and suddenly lose all of your contacts. Those players mentioned will be available, too, for Mays and Walsh-Jennings and Casey Jennings have made it a point to schedule around the AVP as well as four- and five-star FIVBS. The plan is to have the best in the world, playing for the best prize money in the game, with some music and entertainment to cap the night. It's a lot. It's big. It's potentially transformative. It might work, it might not. That's part of the excitement around this movement. And maybe that all sounds a bit crazy, though it is worth reminding that the most successful ideas and businesses were, at one point or other, invariably labeled “crazy.” As Walsh-Jennings wrote on Instagram: “It's go time.”